Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Celltrion Healthcare

- PMLiVE

GSK buys cancer firm Tesaro for $5.1bn

Acquisition re-establishes US commercial operations in oncology

- PMLiVE

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech

- PMLiVE

Astellas, Catalyst approvals set up record year for FDA approvals

2018 is already well ahead of last year's tally

- PMLiVE

Chi-Med and Lilly’s cancer drug Elunate a milestone for China

Partners tap into expanding market - but have multinationals to compete with

- PMLiVE

AZ drug matched to cancer mutation passes phase 2 test

More data from promising class of targeted small molecule drugs

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

- PMLiVE

Soon-Shiong presents first data on cancer memory vaccine at SITC

Novel cocktail shows modest gains in prostate cancer

- PMLiVE

Is GSK planning to exit the respiratory business?

Oncology head says opportunities diminishing despite firm's heritage

- PMLiVE

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

- PMLiVE

Merck’s Bavencio joins first-line kidney cancer face-off

PD-L1 and TKI combination could challenge standard of care

- PMLiVE

Dynavax is ‘deal-ready’ after solid ESMO data; analyst

Contrasting results for two novel immunotherapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links